L-arginine supplementation accelerates renal fibrosis and shortens life span in experimental lupus nephritis

Kidney International

Volumn 63, Issue 4, 2003, Pages 1382-1392

  Peters, Harm ^a   Border, Wayne A ^b   Rückert, Matthias ^b   Krämer, Stephanie ^b   Neumayer, Hans H ^b   Noble, Nancy A ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NONE

Author keywords

Fibrosis; L Arginine; Nitric oxide; TGF

Indexed keywords

ARGININE; CITRULLINE; DNA ANTIBODY; FIBRONECTIN; IMMUNOGLOBULIN G; MESSENGER RNA; NITRATE; NITRIC OXIDE SYNTHASE; NITRITE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA1; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CYTOTOXICITY; DIET SUPPLEMENTATION; DISEASE SEVERITY; FEMALE; INFLAMMATORY CELL; KIDNEY CELL; KIDNEY FIBROSIS; LIFESPAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DIET; PROTEIN EXPRESSION; PROTEIN RESTRICTION; PROTEINURIA; SURVIVAL; UREA NITROGEN BLOOD LEVEL;

EID: 0037378409     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00881.x     Document Type: Article

References (55)

1. REYES AA, KARL IE, KLAHR S: Role of arginine in health and in renal disease. Am J Physiol 267:F331-F346, 1994
2. KONE BC: Nitric oxide in renal health and disease. Am J Kidney Dis 30:311-333, 1997
3. MONCADA S, HIGGS A: The L-arginine-nitric oxide pathway. N Engl J Med 329:2002-2012, 1993
4. PETERS H, BORDER WA, NOBLE NA: From rats to man: A perspective on dietary L-arginine supplementation in human renal disease. Nephrol Dial Transplant 14:1640-1650, 1999
5. BARBUL A: Arginine: Biochemistry, physiology, and therapeutic implications. J Parenter Enteral Nutr 10:227-238, 1986
6. CASTILLO L, AJAMI A, BRANCH S, et al: Plasma arginine kinetics in adult man: Response to an arginine-free diet. Metabolism 43:114-122, 1994
7. PETERS H, BORDER WA, NOBLE NA: Angiotensin II and L-arginine in tissue fibrosis: More than blood pressure. Kidney Int 51:1481-1486, 1997
8. LORTIE MJ, NOVOTNY WF, PETERSON OW, et al: Agmatine, a bioactive metabolite of arginine. Production, degradation, and functional effects in the kidney of the rat. J Clin Invest 97:413-420, 1996
9. BLANTZ RC, SATRIANO J, GABBAI F, KELLY C: Biological effects of arginine metabolites. Acta Physiol Scand 168:21-25, 2000
10. NARITA I, BORDER WA, KETTELER M, NOBLE NA: Nitric oxide mediates immunologic injury to kidney mesangium in experimental glomerulonephritis. Lab Invest 72:17-24, 1995
11. NOIRI E, PERESLENI T, MILLER F, GOLIGORSKY MS: In vivo targeting of inducible NO synthase with oligodeoxynucleotides protects rat kidney against ischemia. J Clin Invest 97:2377-2383, 1996
12. WEINBERG JB, GRANGER DL, PISETSKY DS, et al: The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: Increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine. J Exp Med 179:651-660, 1994
13. PETERS H, BORDER WA, NOBLE NA: L-Arginine supplementation increases mesangial cell injury and subsequent tissue fibrosis in experimental glomerulonephritis. Kidney Int 55:2264-2273, 1999
14. PETERS H, BORDER WA, NOBLE NA: Tandem antifibrotic actions of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis. Kidney Int 57:922-1001, 2000
15. REYES AA, KLAHR S: Dietary supplementation of L-arginine ameliorates renal hypertrophy in rats fed a high-protein diet. Proc Soc Exp Biol Med 206:157-161, 1994
16. KATOH T, TAKAHASHI K, KLAHR S, et al: Dietary supplementation with L-arginine ameliorates glomerular hypertension in rats with subtotal nephrectomy. J Am Soc Nephrol 4:1690-1694, 1994
17. REYES AA, PORRAS BH, CHASALOW FI, KLAHR S: L-Arginine decreases the infiltration of the kidney by macrophages in obstructive nephropathy and puromycin-induced nephrosis. Kidney Int 45:1346-1354, 1994
18. REYES AA, KARL IE, YATES J, KLAHR S: Low plasma and renal tissue levels of L-arginine in rats with obstructive nephropathy. Kidney Int 45:782-787, 1994
19. CHEN PY, SANDERS PW: L-Arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest 88:1559-1567, 1991
20. CHEN PY, ST. JOHN PL, KIRK KA, et al: Hypertensive nephrosclerosis in the Dahl/Rapp rat. Initial sites of injury and effect of dietary L-arginine supplementation. Lab Invest 68:174-184, 1993
21. DE NICOLA L, THOMSON SC, WEAD LM, et al: Arginine feeding modifies cyclosporine nephrotoxicity in rats. J Clin Invest 92:1859-1865, 1993
22. THEOFILOPOULOS AN, PRUD́HOMME GJ, DIXON FJ: Autoimmune aspects of systemic lupus erythematosus, in Autoimmunity: Basic Concepts, Systemic and Selected Organ-Specific Diseases, edited by CRUSE JM, LEWIS J, Basel, Karger Verlag 1985, pp 190-218
23. WATANABE-FUKUNAGA R, BRANNAN CI, COPELAND NG, et al: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314-317, 1992
24. BORDER WA, NOBLE NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 331:1286-1292, 1994
25. PETERS H, NOBLE NA, BORDER WA: Targeting TGF-β overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 54:1575-1583, 1998
26. HALL AV, PARBTANI A, CLARK WF, et al: Abrogation of MRL/lpr lupus nephritis by dietary flaxseed. Am J Kidney Dis 22:326-332, 1993
27. AUSTIN HA, MUENZ LR, JOYCE KM, et al: Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 75:382-391, 1983
28. SCHUSTER R: Determination of amino acids in biological, pharmaceutical, plant and food samples by automated precolumn derivatization and high-performance liquid chromotography. J Chromo 431:271-284, 1988
29. RENNARD SI, BERG R, MARTIN GR, et al: Enzyme-linked immunoassay (ELISA) for connective tissue components. Anal Biochem 104:205-214, 1980
30. REDDY GK, ENWEMEKA CS: A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 29:225-229, 1996
31. GREEN LC, WAGNER DA, GLOGOWSKI J, et al: Analysis of nitrate, nitrite and 15N-nitrate in biological fluids. Anal Biochem 126:131-138, 1982
32. GILKESON GS, RUIZ P, GRUDIER JP, et al: Genetic control of inflammatory arthritis in congenic lpr mice. Clin Immunol Immunopathol 53:460-474, 1989
33. CHRISTENSEN E: Multivariate survival analysis using Cox's regression model. Hepatology 7:1346-1358, 1987
34. OATES JC, RUIZ P, ALEXANDER A, et al: Effect of late modulation of nitric oxide production on murine lupus. Clin Immunol Immunopathol 83:86-92, 1997
35. PETERS H, BORDER WA, NOBLE NA: Angiotensin II blockade and low protein diet produce additive therapeutic effects on experimental glomerulonephritis. Kidney Int 57:1493-1501, 1999
36. KETTELER M, IKEGAYA N, BREES DK, et al: L-Arginine metabolism in immune-mediated glomerulonephritis in the rat. Am J Kidney Dis 28:878-887, 1996
37. ALBINA JE, CUI S, MATEO RB, REICHNER JS: Nitric oxide-mediated apoptosis in murine peritoneal macrophages. J Immunol 150:5080-5085, 1993
38. MULLIGAN MS, HEVEL JM, MARLETTA MA, WARD PA: Tissue injury caused by deposition of immune complexes is L-arginine dependent. Proc Natl Acad Sci USA 88:6338-6342, 1991
39. NOZIK ES, HUANG YC, PIANTADOSI CA: L-Arginine enhances injury in the isolated rabbit lung during hyperoxia. Respir Physiol 100:63-74, 1995
40. NEILLY PJ, KIRK SJ, GARDINER KR, et al: Manipulation of the L-arginine-nitric oxide pathway in experimental colitis. Br J Surg 82:1188-1191, 1995
41. ZHANG F, CASEY RM, ROSS ME, IADECOLA C: Aminoguanidine ameliorates and L-arginine worsens brain damage from intraluminal middle cerebral artery occlusion. Stroke 27:317-323, 1996
42. KASHEM A, ENDOH M, YANO N, et al: Expression of inducible-NOS in human glomerulonephritis: The possible source is infiltrating monocytes/macrophages. Kidney Int 50:392-399, 1996
43. FURUSU A, MIYAZAKI M, ABE K, et al: Expression of endothelial and inducible nitric oxide synthase in human glomerulonephritis. Kidney Int 53:1760-1768, 1998
44. HEERINGA P, BUL M, JAGER-KRIKKEN A, et al: Renal expression of endothelial and inducible nitric oxide synthase, and formation of peroxynitrite-modified proteins and reactive oxygen species in Wegener's granulomatosis. J Pathol 193:224-232, 2001
45. MACMILLAN CROW LA, CROW JP, et al: Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc Natl Acad Sci USA 93:11853-11858, 1996
46. JANSEN A, COOK T, TAYLOR GM, et al: Induction of nitric oxide synthase in rat immune complex glomerulonephritis. Kidney Int 45:1215-1219, 1994
47. WADDINGTON S, COOK TH, REAVELEY D, et al: L-Arginine depletion inhibits glomerular nitric oxide synthesis and exacerbates rat nephrotoxic nephritis. Kidney Int 49:1090-1096, 1996
48. CATTELL V: Nitric oxide and glomerulonephritis. Kidney Int 61:816-821, 2002
49. CATTELL V: Nitric oxide-potential mediator in glomerulonephritis? Nephrol Dial Transplant 10:759-774, 1995
50. CATTELL V, COOK HT, EBRAHIM H, et al: Anti-GBM glomerulonephritis in mice lacking nitric oxide synthase type 2. Kidney Int 53:932-936, 1998
51. VOS IH, JOLES JA, SCHURINK M, et al: Inhibition of inducible nitric oxide synthase improves graft function and reduces tubulointerstitial injury in renal allograft rejection. Eur J Pharmacol 391:31-38, 2000
52. VOS IH, RABELINK TJ, DORLAND B, et al: L-Arginine supplementation improves function and reduces inflammation in renal allografts. J Am Soc Nephrol 12:361-367, 2001
53. ISHIZUKA S, CUNARD R, POUCELL-HATTON S, et al: Agmatine inhibits cell proliferation and improves renal function in anti-thy-1 glomerulonephritis. J Am Soc Nephrol 11:2256-2264, 2000
54. WU G, MEININGER CJ: Arginine nutrition and cardiovascular function. J Nutr 130:2626-2629, 2000
55. DE NICOLA L, BELLIZZI V, MINUTOLO R, et al: Randomized, double-blind, placebo-controlled study of arginine supplementation in chronic renal failure. Kidney Int 56:674-684, 1999